| Literature DB >> 27733308 |
Maeghan O'Neill1, Cristina Ballesteros1, Lucienne Tritten1, Erica Burkman2, Weam I Zaky3, Jianguo Xia4, Andrew Moorhead2, Steven A Williams3, Timothy G Geary5.
Abstract
The use of microfilaricidal drugs for the control of onchocerciasis and lymphatic filariasis (LF) necessitates prolonged yearly dosing. Prospects for elimination or eradication of these diseases would be enhanced by the availability of a macrofilaricidal drug. Flubendazole (FLBZ), a benzimidazole anthelmintic, is an appealing candidate. FLBZ has demonstrated potent macrofilaricidal effects in a number of experimental rodent models and in one human trial. Unfortunately, FLBZ was deemed unsatisfactory for use in mass drug administration campaigns due to its limited oral bioavailability. A new formulation that enables sufficient bioavailability following oral administration could render FLBZ an effective treatment for onchocerciasis and LF. Identification of drug-derived effects is important in ascertaining a dosage regimen which is predicted to be lethal to the parasite in situ. In previous histological studies, exposure to FLBZ induced damage to tissues required for reproduction and survival at pharmacologically relevant concentrations. However, more precise and quantitative indices of drug effects are needed. This study assessed drug effects using a transcriptomic approach to confirm effects observed histologically and to identify genes which were differentially expressed in treated adult female Brugia malayi. Comparative analysis across different concentrations (1 μM and 5 μM) and durations (48 and 120 h) provided an overview of the processes which are affected by FLBZ exposure. Genes with dysregulated expression were consistent with the reproductive effects observed via histology in our previous studies. This study revealed transcriptional changes in genes involved in embryo development. Additionally, significant downregulation was observed in genes encoding cuticle components, which may reflect changes in developing embryos, the adult worm cuticle or both. These data support the hypothesis that FLBZ acts predominantly on rapidly dividing cells, and provides a basis for selecting molecular markers of drug-induced damage which may be of use in predicting efficacious FLBZ regimens.Entities:
Keywords: Benzimidazole; Cuticle; Filariasis; Flubendazole; Macrofilaricide; RNAseq; Reproduction
Year: 2016 PMID: 27733308 PMCID: PMC5196492 DOI: 10.1016/j.ijpddr.2016.09.005
Source DB: PubMed Journal: Int J Parasitol Drugs Drug Resist ISSN: 2211-3207 Impact factor: 4.077
Study design. Worms were randomly allocated to one of three treatment groups. At each time point, three groups of 10 worms were washed, flash-frozen and used for RNA extraction.
| Treatment group | Time to RNA isolation after arrival | |
|---|---|---|
| 2 Days | 5 Days | |
| Control (0.1% DMSO) | 3 × 10 worms | 3 × 10 worms |
| 1 μM Flubendazole | 3 × 10 worms | 3 × 10 worms |
| 5 μM Flubendazole | 3 × 10 worms | 3 × 10 worms |
RNA sequencing summary. Picard alignment summary tool was used to summarize the sequencing and mapping of sequences to the B. malayi transcriptome.
| Treatment group | Average total # of reads | Aligned reads (%) | High quality alignments (%) | # Of transcripts | |
|---|---|---|---|---|---|
| 48 h | Control | 2805561 | 99.9 | 82.7 | 9329 |
| FLBZ 1 μM | 1724686 | 99.9 | 82.8 | 8864 | |
| FLBZ 5 μM | 2065240 | 99.9 | 82.3 | 9076 | |
| 120 h | Control | 2462188 | 99.9 | 81.8 | 9054 |
| FLBZ 1 μM | 2087268 | 99.9 | 81.1 | 8827 | |
| FLBZ 5 μM | 2771021 | 99.9 | 81.8 | 9126 | |
Summary of differential gene expression analysis.
| Time point | Treatment group | Upregulated genes | Downregulated genes | Total # of DEGs | Genes with |
|---|---|---|---|---|---|
| 48 h | FLBZ 1 μM | 18 | 80 | 98 | 77 |
| FLBZ 5 μM | 62 | 32 | 94 | 72 | |
| 120 h | FLBZ 1 μM | 24 | 135 | 159 | 115 |
| FLBZ 5 μM | 19 | 104 | 123 | 77 |
Fig. 1Volcano plot of all differentially expressed genes. Green dots denote significantly differentially expressed genes (FDR<0.15) and black dots symbolize those which are not significant. The x-axis is the fold difference (log 2) between groups and the y-axis represents the log10 of the p-value.
Fig. 2DE genes that overlap among treatment groups. Venn diagram created in Venny 2.0.2.
Fig. 3Gene ontology analysis of DE genes associated with FLBZ exposure. Up-regulated (A) and down-regulated (B) genes were manually assigned to GO terms using information available in Wormbase.
Fig. 4Correlation between qPCR and RNAseq data. The correlation coefficient between RNAseq (x-axis) and qPCR (y-axis) data (log2 fold-change) analyzed by the Pearson test was 0.9978 with a statistical significance p < 0.05.
GO term enrichment. Top biological processes and molecular functions associated with C. elegans orthologues of B. malayi genes curated using UniProt. Statistically significantly enriched GO terms are reported as p-value.
| GO term | GO ID | 48 h | 120 h | ||
|---|---|---|---|---|---|
| FLBZ 1 μM | FLBZ 5 μM | FLBZ 1 μM | FLBZ 5 μM | ||
| Anatomical structure development | GO:0048856 | 6.46E-06 | |||
| Multicellular organismal development | GO:0007275 | 2.94E-05 | |||
| Cell cycle process | GO:0022402 | 7.46E-05 | |||
| M phase | GO:0000279 | 9.28E-05 | |||
| Mitotic chromosome condensation | GO:0007076 | 9.91E-05 | |||
| Cell cycle | GO:0007049 | 0.0001 | |||
| Cell cycle phase | GO:0022403 | 1.00E-04 | |||
| Body morphogenesis | GO:0010171 | 0.0001 | 0.084 | ||
| Developmental process | GO:0032502 | 2.00E-04 | |||
| Anatomical structure morphogenesis | GO:0009653 | 3.00E-04 | |||
| Larval development | GO:0002164 | 0.0012 | 0.01 | ||
| Locomotion | GO:0040011 | 0.0018 | 0.0033 | ||
| Tissue development | GO:0009888 | 0.0046 | 0.0087 | ||
| Regulation of growth rate | GO:0040009 | 0.0085 | |||
| Molting cycle | GO:0042303 | 0.0067 | |||
| Positive regulation of growth rate | GO:0040010 | 0.0084 | |||
| Molting cycle, collagen and cuticulin-based cuticle | GO:0018996 | 0.0067 | |||
| Positive regulation of growth | GO:0045927 | 0.0031 | |||
| Regulation of growth | GO:0040008 | 0.0047 | |||
| Collagen and cuticulin-based cuticle development | GO:0040002 | 0.0087 | |||
| ATP binding | GO:0005524 | 8.23E-07 | |||
| Adenyl ribonucleotide binding | GO:0032559 | 8.38E-07 | |||
| Adenyl nucleotide binding | GO:0030554 | 8.38E-07 | |||
| Motor activity | GO:0003774 | 6.03E-06 | |||
| Purine ribonucleoside triphosphate binding | GO:0035639 | 1.15E-05 | |||
| Purine ribonucleoside binding | GO:0032550 | 1.17E-05 | |||
| Purine ribonucleotide binding | GO:0032555 | 1.18E-05 | |||
| Purine nucleotide binding | GO:0017076 | 1.18E-05 | |||
| Nucleoside binding | GO:0001882 | 1.24E-05 | |||
| Ribonucleoside binding | GO:0032549 | 1.24E-05 | |||
| Structural molecule activity | GO:0005198 | 1.51E-02 | 3.95E-05 | 2.31E-07 | 1.03E-08 |
| Structural constituent of cuticle | GO:0042302 | 8.37E-09 | 2.84E-09 | ||